{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:12:22Z","timestamp":1789697542578,"version":"4.0.1"},"reference-count":102,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate from the epithelial lining of the biliary tree. BTCs are characterized by presentation with advanced disease precluding curative surgery, rising global incidence, and a poor prognosis. Chemotherapy is the mainstay of the current treatment, which results in a median overall survival of less than one year, underscoring the need for novel therapeutic agents and strategies. Next-generation sequencing-based molecular profiling has shed light on the underpinnings of the complex pathophysiology of BTC and has uncovered numerous actionable targets, leading to the discovery of new therapies tailored to the molecular targets. Therapies targeting fibroblast growth factor receptor (FGFR) fusion, isocitrate dehydrogenase (IDH) mutations, the human epidermal growth factor receptor (HER) family, DNA damage repair (DDR) pathways, and BRAF mutations have produced early encouraging results in selected patients. Current clinical trials evaluating targeted therapies, as monotherapies and in combination with other agents, are paving the way for novel treatment options. Genomic profiling of cell-free circulating tumor DNA that can assist in the identification of an actionable target is another exciting area of development. In this review, we provide a contemporaneous appraisal of the evolving targeted therapies and the ongoing clinical trials that will likely transform the therapeutic paradigm of BTC.<\/jats:p>","DOI":"10.3390\/cancers12082039","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T09:06:09Z","timestamp":1595581569000},"page":"2039","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-098X","authenticated-orcid":false,"given":"Sakti","family":"Chakrabarti","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-2712","authenticated-orcid":false,"given":"Mandana","family":"Kamgar","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-8333","authenticated-orcid":false,"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.cgh.2012.09.009","article-title":"Classification, diagnosis, and management of cholangiocarcinoma","volume":"11","author":"Razumilava","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11894-011-0178-8","article-title":"Cholangiocarcinoma: Epidemiology, risk factors, pathogenesis, and diagnosis","volume":"13","author":"Charbel","year":"2011","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"vii345","DOI":"10.1093\/annonc\/mdq420","article-title":"Advances in the treatment of metastatic or unresectable biliary tract cancer","volume":"21","author":"Valle","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","article-title":"Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy","volume":"31","author":"Wang","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","article-title":"Second-line therapies in advanced biliary tract cancers","volume":"21","author":"Tella","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000011961","article-title":"Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer","volume":"56","author":"Raderer","year":"1999","journal-title":"Oncology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","article-title":"Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine","volume":"30","author":"Sasaki","year":"2012","journal-title":"Invest. New Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/bjc.2016.446","article-title":"Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: Retrospective analysis of 321 patients","volume":"116","author":"Kim","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: A systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/s41598-019-42069-1","article-title":"Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis","volume":"9","author":"Moik","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","article-title":"ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin\/5-FU chemotherapy (ASC + mFOLFOX) for patients (pts) with locally advanced\/metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy","volume":"37","author":"Lamarca","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41416-018-0138-2","article-title":"A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin","volume":"119","author":"Zheng","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Neuzillet, C., Casadei-Gardini, A., Brieau, B., Vivaldi, C., Brandi, G., Tougeron, D., Filippi, R., Vienot, A., Silvestris, N., and Pointet, A.-L. (2020). Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. Int. J. Cancer.","DOI":"10.1002\/ijc.33146"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41416-019-0698-9","article-title":"Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: An open-label, single arm, phase 2 trial","volume":"122","author":"Belkouz","year":"2020","journal-title":"Brit. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1634\/theoncologist.2019-0874","article-title":"Phase II Trial of Trifluridine\/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma","volume":"25","author":"Chakrabarti","year":"2020","journal-title":"Oncologist"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Churi, C.R., Shroff, R., Wang, Y., Rashid, A., Kang, H.C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., and Meric-Bernstam, F. (2014). Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115383"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: Potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \"prime time\" in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12885-020-06804-6","article-title":"Distinct clinical and prognostic implication of IDH1\/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/PO.18.00414","article-title":"Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients","volume":"4","author":"Cao","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jss.2013.06.028","article-title":"Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology: 10-y review of the literature","volume":"184","author":"Burnett","year":"2013","journal-title":"J. Surg. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_35","first-page":"1","article-title":"Comprehensive Genomic Landscape and Precision Therapeutic Approach in Biliary Tract Cancers","volume":"10","author":"Okamura","year":"2020","journal-title":"SSRN Electron. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13261","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cca.2016.05.007","article-title":"Screening for circulating RAS\/RAF mutations by multiplex digital PCR","volume":"458","author":"Andersen","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00324","article-title":"Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers","volume":"3","author":"Mody","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Dasari, A., Morris, V.K., Allegra, C.J., Atreya, C., Benson, A.B., Boland, P., Chung, K., Copur, M.S., Corcoran, R.B., and Deming, D.A. (2020). ctDNA applications and integration in colorectal cancer: An NCI Colon and Rectal\u2013Anal Task Forces whitepaper. Nat. Rev. Clin. Oncol., 1\u201314.","DOI":"10.1038\/s41571-020-0392-0"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_43","first-page":"ix46","article-title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors","volume":"29","author":"Arkenau","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2020.38.15_suppl.108","article-title":"FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements","volume":"38","author":"Goyal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","article-title":"Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations","volume":"37","author":"Park","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"AB065","DOI":"10.21037\/hbsn.2019.AB065","article-title":"AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: Preliminary results","volume":"8","author":"Ng","year":"2019","journal-title":"Hepatobiliary Surg. Nutr. (3rd Asia-Pacific Cholangiocarcinoma Conference)"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2019.37.4_suppl.187","article-title":"Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial","volume":"37","author":"Wainberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Harding, J.J., Cleary, J., Shapiro, G., Bra\u00f1a, I., Moreno, V., Quinn, D., Borad, M., Loi, S., Spanggaard, I., and Stemmer, S.M. (2019, January 3\u20136). Treating HER2-mutant advanced biliary tract cancer with neratinib: Benefits of HER2-directed targeted therapy in the phase 2 SUMMIT \u201cbasket\u201d trial. Proceedings of the ESMO World Congress on Gastrointestinal Cancer, Barcelona, Spain. Abstract Number O-005.","DOI":"10.1093\/annonc\/mdz154.004"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2019.37.4_suppl.345","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial","volume":"37","author":"Demols","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2020.38.15_suppl.4597","article-title":"Results from TreeTopp: A randomized phase II study of the e!cacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC)","volume":"38","author":"Javle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR Signaling in Cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"F1577","DOI":"10.1152\/ajprenal.00463.2006","article-title":"Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro","volume":"293","author":"Perwad","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15014","DOI":"10.18632\/oncotarget.14788","article-title":"Acquired resistance to LY2874455 in FGFR2 -amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion","volume":"8","author":"Ahn","year":"2017","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke\u2013related and non-infection-related bile duct cancers","volume":"45","author":"Ong","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: A systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3892\/or.2014.3261","article-title":"Characterization of EGFR family gene aberrations in cholangiocarcinoma","volume":"32","author":"Yang","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2017.35.4_suppl.402","article-title":"Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway","volume":"35","author":"Javle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Moehler, M., Maderer, A., Ehrlich, A., Foerster, F., Schad, A., Nickolay, T., Ruckes, C., Weinmann, A., Sivanathan, V., and Marquardt, J.U. (2019). Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine\/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, phase I trial with an extensive biomarker program. BMC Cancer, 19.","DOI":"10.1186\/s12885-018-5223-7"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336488","article-title":"HER2\/neu may not be an interesting target in biliary cancers: Results of an early phase II study with lapatinib","volume":"82","author":"Peck","year":"2012","journal-title":"Oncology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1200\/JCO.2019.37.4_suppl.331","article-title":"Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies","volume":"37","author":"Tan","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2019.37.15_suppl.4085","article-title":"Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI)","volume":"37","author":"Spizzo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"TPS4153","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4153","article-title":"A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer","volume":"37","author":"Sahai","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"556","DOI":"10.21037\/jgo.2016.03.05","article-title":"BRCA-associated protein 1 mutant cholangiocarcinoma: An aggressive disease subtype","volume":"7","author":"Anand","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Bridgewater, J., Lopes, A., Beare, S., Duggan, M., Lee, D., Ricamara, M., McEntee, D., Sukumaran, A., Wasan, H., and Valle, J.W. (2016). A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: The ABC-04 study. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2174-8"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Phelps","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wu, C.E., Chen, M.H., and Yeh, C.N. (2019). mTOR Inhibitors in Advanced Biliary Tract Cancers. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030500"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Deshpande, V., Nduaguba, A., Zimmerman, S.M., Kehoe, S.M., MacConaill, L.E., Lauwers, G.Y., Ferrone, C., Bardeesy, N., Zhu, A.X., and Hezel, A.F. (2011). Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-60"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e14500","DOI":"10.1200\/jco.2010.28.15_suppl.e14500","article-title":"Efficacy and safety of RAD001 in advanced biliary tract cancer (BTC) patients (pts) progressing after first-line chemotherapy: A phase II study","volume":"28","author":"Buzzoni","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41416-018-0021-1","article-title":"Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: The RADiChol Study","volume":"118","author":"Lau","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/bjc.2017.428","article-title":"Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer","volume":"118","author":"Kim","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11596-017-1711-2","article-title":"Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials","volume":"37","author":"Zhuang","year":"2017","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): A randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Brit. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"v246","DOI":"10.1093\/annonc\/mdx369.106","article-title":"722P\u2014A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results","volume":"28","author":"Ikeda","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: The VanGogh study","volume":"26","author":"Santoro","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Gu, T.L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V., Wang, Y., Deng, G., Zhu, L., and Tan, Z. (2011). Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0015640"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-06-0818","article-title":"Targeting the c-Met signaling pathway in cancer","volume":"12","author":"Peruzzi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdu157","article-title":"A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors","volume":"25","author":"Pant","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.2020.38.4_suppl.477","article-title":"Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study","volume":"38","author":"Valle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/cco.2019.12.10","article-title":"Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)","volume":"9","author":"Jakubowski","year":"2020","journal-title":"Chin. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1634\/theoncologist.2018-0044","article-title":"Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)","volume":"23","author":"Arkenau","year":"2018","journal-title":"Oncologist"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Lin, J., Yang, X., Long, J., Zhao, S., Mao, J., and Wang, D. (2020). Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg. Nutr.","DOI":"10.21037\/hbsn-20-338"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yarchoan, M., Cope, L., Anders, R.A., Noonan, A., Goff, L.W., and Goyal, L. (2020, January 28). CT043\u2014A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study. Proceedings of the AACR Virtual Annual Meeting, Los Angeles, CA, USA.","DOI":"10.1158\/1538-7445.AM2020-CT043"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00371","article-title":"Comparative Analysis of Public Knowledge Bases for Precision Oncology","volume":"3","author":"Pallarz","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"14957","DOI":"10.18632\/oncotarget.14844","article-title":"Intratumoral heterogeneity of intrahepatic cholangiocarcinoma","volume":"8","author":"Walter","year":"2017","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2039\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:28Z","timestamp":1760176288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":102,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082039"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082039","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}